HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Audiologist Group Has Concerns About US FDA's Proposal For OTC Sales Of Hearing Aids

ASHA Survey Shows Consumers Unaware Of Or Don't Understand Proposed Rule

Executive Summary

With FDA proposal to allow OTC hearing aid sales mostly met with approval, American Speech-Language-Hearing Association says consumers risk further hearing loss by not consulting with professionals.

You may also be interested in...



Senators Emphasize Federal Pre-emption In US OTC Hearing Aid Rule, State Attorneys General Disagree

Warren and Grassley say legislation instructing FDA to establish OTC sales of some hearing aids stated a federal regulation is needed to ensure consumers in all states benefit from the change. State AGs, on the other hand, ask FDA to “define preemption terms in a way that recognizes the important role state and local entities play in protecting consumers.”

No Prescription? No Problem: US FDA Draft Rule Gives Green Light To OTC Hearing Aids

FDA’s proposed rule aims to get more hearing aids into the ears of consumers who need them by allowing OTC sales of the devices. Proposal follows a a July executive order by President Biden directing HHS to issue proposed rules for OTC hearing aids within 120 days.

No Prescription? No Problem: FDA Draft Rule Gives Green Light To OTC Hearing Aids

The US FDA’s proposed reg, released on 19 October, aims to get more hearing aids into the ears of those who need them by allowing the devices to be purchased over the counter.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151877

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel